Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02350829
Recruitment Status : Unknown
Verified April 2015 by Lars Grosse-Wortmann, The Hospital for Sick Children.
Recruitment status was:  Recruiting
First Posted : January 30, 2015
Last Update Posted : April 16, 2015
Sponsor:
Information provided by (Responsible Party):
Lars Grosse-Wortmann, The Hospital for Sick Children

Brief Summary:

Diffuse fibrosis (or scarring) of the heart muscle is found in a variety of congenital heart diseases and in cardiomyopathies (heart muscle disease), and is considered a mediator of decreased cardiac function. The detection and quantification of diffuse myocardial fibrosis has recently become feasible non-invasively, using cardiac magnetic resonance (CMR), applying a new technique labeled T1 mapping. With this technique, the part of the heart tissue which is not made up of muscle cells (extracellular volume) can be quantified, as long as the individual's hematocrit (cellular volume in the blood) is known. The extracellular volume in the heart tissue is regarded as a quantifiable marker for the extent of diffuse myocardial fibrosis.

In the proposed study this new T1 mapping technique shall be applied in patients with different forms of congenital heart disease (n=130), cardiomyopathies (n=40) and in control subjects (n=30). The additional scan time due to participation in the study will be approximately 5-10 minutes, without changing the clinical protocol.

The main objective is to study the presence and extent of myocardial fibrosis by T1 mapping CMR in pediatric patients with congenital heart disease and cardiomyopathies, in comparison to cardiovascularly healthy controls.


Condition or disease Intervention/treatment Phase
Cardiomyopathy Other: Cardiac magnetic resonance sequence T1 mapping Not Applicable

Detailed Description:

A better understanding of the mechanisms by which the heart muscle fails in pediatric heart disease may result in novel therapies directed at preventing rather than treating ventricular failure. The most likely mediator candidate for cardiac demise in congenital heart disease as well as the cardiomyopathies is diffuse myocardial fibrosis and non-favorable chronic biventricular remodeling. As such, fibrosis may be a marker, if not a mediator, preceding the onset of actual echocardiographic and clinical deterioration, opening opportunities for more timely and targeted treatment. Chronic stressors of myocardial function (hypoxemia, abnormal afterload or preload) appear to promote fibrosis. In some groups of patients, a genetically upregulated collagen metabolism seems to play a role. In adult patients with dilated cardiomyopathy the extent of myocardial fibrosis is predictive of outcome.

With cardiac magnetic resonance imaging, the characterization of myocardial tissue is possible. Whereas standard late gadolinium enhancement (LGE) CMR can only identify patchy scars neighboring healthy tissue, quantification of diffuse myocardial fibrosis in the living has become feasible with the T1 mapping technique. Both techniques (T1 mapping and LGE) are based on the principle that MR contrast medium (gadolinium) is trapped in between collagen fibres and is retained in areas of fibrosis while it is quickly washed out of healthy myocardium. As gadolinium is a T1 shortening agent, the fibrosed tissue with its 'trapped' gadolinium has a shorter T1 time than healthy tissue. T1 mapping measures the T1 time constant, which has been shown to correlate with the degree of fibrosis. In a refined approach of this technique, which we will use, it is now possible to quantify the extracellular space (equivalent to the degree of fibrosis) by T1 mapping. This method has been validated against the current gold standard of surgical myocardial biopsy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Quantification of Diffuse Myocardial Fibrosis in Children With Cardiomyopathy or Congenital Heart Disease by T1 Mapping Cardiac Magnetic Resonance
Study Start Date : February 2014
Estimated Primary Completion Date : August 2016
Estimated Study Completion Date : August 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Cardiomyopathy

Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy

Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers

Other: Cardiac magnetic resonance sequence T1 mapping
Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers

Active Comparator: Congenital Heart Disease

Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan

Obtaining bloodwork for assessment of hematocrit and collagen biomarkers

Other: Cardiac magnetic resonance sequence T1 mapping
Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers

Active Comparator: Controls
Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
Other: Cardiac magnetic resonance sequence T1 mapping
Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers




Primary Outcome Measures :
  1. Measuring degree of diffuse myocardial fibrosis [ Time Frame: Once at the end of the visit ]
    Participants will be followed for the duration of hospital visit, which is approximately 2 hours for the MRI part, and eventually longer, depending on possible other appointments on that day



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: Patients with cardiomyopathies (clinically established diagnosis of dilated or hypertrophic cardiomyopathy) / Patients with congenital heart disease (Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage) scheduled for an MR investigation including gadolinium (MRI contrast medium)

  • Patients / guardians capable of giving informed consent
  • Informed written consent / assent by the parents / legal guardians and patients where applicable
  • Ability to undergo a MRI examination without anaesthesia. Children > 6 years are typically able to cooperate sufficiently.
  • Control Patients: Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) including gadolinium without a history of cardiac disease

Exclusion Criteria:- Consent / assent refusal by guardian / patient

  • General contraindications for a MRI examination such as non-MRI compatible metallic implants, claustrophobia.
  • No contrast required for the clinical portion of the MRI
  • Patients who require anaesthesia for MRI (typically < 6 years of age)
  • Known renal failure or previous allergic reaction to gadolinium containing contrast agent
  • Control subjects: history of cardiac problems, e.g. rhythm disorders, former myocarditis, active myositis or other inflammatory conditions except suspected or confirmed inflammatory bowel disease such as Crohn's disease or ulcerative colitis
  • Known pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02350829


Contacts
Layout table for location contacts
Contact: Lars Grosse-Wortmann, MD 4168137308 lars.grosse-wortmann@sickkids.ca

Locations
Layout table for location information
Canada, Ontario
Hospital for Sick Children Recruiting
Toronto, Ontario, Canada, M5G 1X8
Sponsors and Collaborators
The Hospital for Sick Children
Investigators
Layout table for investigator information
Principal Investigator: Lars Grosse-Wortmann, MD The Hospital for Sick Children

Layout table for additonal information
Responsible Party: Lars Grosse-Wortmann, Cardiologist, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT02350829     History of Changes
Other Study ID Numbers: 1000039963
First Posted: January 30, 2015    Key Record Dates
Last Update Posted: April 16, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiomyopathies
Heart Defects, Congenital
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities